Anlon Healthcare Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qhjpim7dkpdxgoa0h973toxp.pdf

Key Takeaways


The Capacity Inflection: Acquisitions & Greenfield

Punit Kumar Rasadia: "We have planned that before end of the next financial year, we'll do it the 100 percent subsidiary."

Revenue Trajectory & Seasonality

Punit Kumar Rasadia: "we are believing that, result would be much better than what, 370 to 380 Crores."

New Product Pipeline & Therapeutic Diversification

Punit Kumar Rasadia: "we are one of the largest manufacturer, and we are the only Indian manufacturer. So we'll have the, some kind of, first..."

Margins, Cash Flow & Balance Sheet


Competitive Positioning & Adjacent Bets

Punit Kumar Rasadia: "all the pharma company in India are almost at the same level. See, they are maybe stronger in financial or resources, but at the new technology, what world is changing for biosimilar, peptide, AI, so all the companies are at the same level. So everyone is, having the, equal opportunities."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 consolidated revenue₹170–180 cr (existing products) to ~₹180–200 cr consolidatedFY26
FY27 consolidated revenue₹370–380 cr, described as "very much conservative"FY27
FY28 consolidated revenueAt least ₹650–700 crFY27–28
2 molecule validationsExpected around June–July 2026Q1 FY27
Greenfield expansion completionOperational by 31 March 2027By 31 March 2027
Apiqo & Bizotic become 100% subsidiariesVia share swap to existing shareholdersBefore end of next financial year
Merger of subsidiariesCleared within 3–4 months of becoming 100% subsidiariesAfter 100% subsidiary step
New API launches6 or 7 new APIs commercializedNext financial year
Working capital days180–185 days by FY26 end, 150–160 days next yearFY26 end / next year
Positive operating cash flowAchieved by FY27 end, attempt by H1 FY27 if payment terms acceptedH1 FY27 to FY27 end
Peak debt-to-equity~0.5 to 0.55During expansion phase
Organic expansion plan updatePlanning update expectedBy end of March 2026
Loxoprofen gel/spray DCGI approvalExpected approvalNext-to-next financial year
Peak revenue after all expansionCommitment deferred; update promised after H1 next yearAfter H1 next year

Key Metrics

MetricQ3 FY26
Total income₹35.78 cr, vs ₹9.38 cr in Q3 FY25
EBITDA₹12.54 cr, margin 35.06%
PAT₹5.15 cr, vs a loss in Q3 FY25
Total income (9M FY26)₹121.32 cr, vs ₹71.49 cr in 9M FY25
EBITDA (9M FY26)₹32.56 cr, margin 26.84%
PAT (9M FY26)₹18.02 cr
FY26 revenue guidance₹190–200 cr consolidated, comprising ₹160–170 cr from Anlon and ₹20–25 cr from Apiqo
FY27 revenue guidance₹370–380 cr consolidated, comprising ₹170–180 cr from Anlon, ₹125–130 cr from Apiqo, and ₹75–80 cr from Bizotic
3-year revenue CAGR target~30%
Blended consolidated EBITDA margin30–33%, sustainable across all 3 facilities; Anlon at 35%, Apiqo at ~30%, Bizotic expected at 30–35%
Combined installed capacity1,400–1,600 metric tons per annum across 3 facilities
Existing Anlon facility utilizationMore than 90%, effectively fully utilized
Apiqo Organics utilization80–85%
Bizotic utilization50–55%
Order book for next year (existing plant)₹180–190 cr
Apiqo confirmed order book for next year₹125–130 cr
Working capital days290 days currently; target 180–185 days by FY26 end and 150–160 days next year
DMF filings21 filed; at least 6–7 key molecules expected to be commercialized in next financial year
CDMO molecules under development3 molecules for 2 global innovator companies; 1 validation quantity dispatched, 2 expected by Q1 FY27
Greenfield expansion planned capacity1,200–1,300 metric tons per annum for Anlon, ~500–600 for Apiqo
Greenfield expansion CapEx₹100–120 cr, funded by ₹40–50 cr internal cash flow and ₹50–60 cr bank loan; target debt-to-equity ~0.5–0.55
Revenue concentration from loxoprofen and ketoprofen30–35% of revenue; loxoprofen expected at 25–30% in FY27
New APIs planned for launch in FY27~7 new APIs across additional therapeutic categories
Gestation period for CDMO molecule to commercial revenueMinimum 3–4 years
KSM import dependence on ChinaNone; all KSM sourced indigenously from domestic suppliers